HEALTHJun 14 · 10:00 UTCTHE GUARDIAN WORLDJulia Kollewe

London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

London-based startup Poolbeg Pharma is trialing POLB 001 at six NHS hospitals to prevent cytokine release syndrome in cancer patients undergoing immunotherapy. The company is also developing a GLP-1 weight loss pill.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Poolbeg PharmaorganizationNHSorganizationPOLB 001topiccytokine release syndrometopiccancertopicGLP-1 weight loss pilltopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 23 · 09:00 UTC
Final frontier for meds? UK startup sends drug-making into space
HEALTHJun 4 · 08:48 UTC
Redwood City company develops pill to treat pancreatic cancer, and trial results are promising
HEALTHMay 27 · 00:00 UTC
Could a pill prevent the world’s deadliest cancer?
HEALTHMay 18 · 11:00 UTC
New pancreatic cancer pill could reshape treatment as early trial results stun researchers
HEALTHMay 27 · 14:33 UTC
STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
BUSINESSJun 2 · 17:00 UTC
STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial